21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d2703519e258">More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. </p>

          Related collections

          Author and article information

          Journal
          The Lancet Oncology
          The Lancet Oncology
          Elsevier BV
          14702045
          November 2017
          November 2017
          : 18
          : 11
          : 1483-1492
          Article
          10.1016/S1470-2045(17)30616-2
          28967485
          c0098106-d5f0-4206-b606-337fed056fa1
          © 2017

          Comments

          Comment on this article